Home Featured Page 211

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures...

PTSF83 – Abuse in Psychedelics: Complicity and Groupthink

Addressing Abuse in Psychedelic Spaces

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol...

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...

1...210211212...303 Page 211 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT...

Psychedelic Bulletin: MindMed Announces R(-)-MDMA Program; Psilocybin for Anxiety Study Secures...

PTSF83 – Abuse in Psychedelics: Complicity and Groupthink

Addressing Abuse in Psychedelic Spaces

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol...

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery...

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY